ClinicalTrials.gg
CompletedNCT04102020VIALE-MUpdated Apr 8, 2026Results posted

A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy

A Phase 3 interventional study of Venetoclax and Azacitidine in Acute Myeloid Leukemia (AML), sponsored by AbbVie. Completed at 156 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-08.

Sponsored by AbbVie · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
112
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 202 studies testing venetoclax in Leukemia, Myeloid, Acute — 116 open to participants now, 144 under way, 21 of them phase 3. venetoclax · Leukemia, Myeloid, Acute.

Enrollment
63rd of 202
112 · median 57
Started
2020
with 15 others
Phase 3
16 of 202
7 open now
Registered
38th of 202
by date
Lead sponsor
15 of 202
AbbVie

Among the 202 studies testing venetoclax in Leukemia, Myeloid, Acute, this one is the 63rd largest by enrollment, is one of 16 that started in 2020, is one of 16 in phase 3, and was the 38th registered.

Leukemia, Myeloid, Acute

3,669 studies on the registry are indexed under Leukemia, Myeloid, Acute; 816 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

116 of the 202 studies testing venetoclax in Leukemia, Myeloid, Acute are open now, in 12 countries. Recruiting first, the newest first:

111 more — sign in →

By country, each count listing its studies:

All 116 open studies →

About venetoclax

venetoclax: first FDA approval 2016 (VENCLEXTA), first EMA approval 2016. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 625 Leukemia, Myeloid, Acute studies recruiting now, 363 (58%) set no upper age limit and 222 (36%) stop at 75 or younger; 145 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 202 studies testing venetoclax in Leukemia, Myeloid, Acute, or all of them as a file.
02

Study summary

This study will be conducted in two parts. Part 1 will be the Dose Confirmation portion to determine recommended Phase 3 dose (RPTD) of venetoclax in combination with azacitidine (AZA). Part 3 will be the Dose Finding portion to determine RPTD of venetoclax in combination with AZA. Part 2 and Part 3 Randomization of the study were removed.

03

Conditions studied

  • Acute Myeloid Leukemia (AML)

Keywords

  • Acute myeloid leukemia (AML)
  • Venetoclax
  • Azacitidine (AZA)
  • Maintenance Therapy
  • Conventional Chemotherapy
  • Best supportive care (BSC)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of newly diagnosed acute myeloid leukemia (AML).
  • Participant meets the following disease activity criteria:

    • Confirmation of AML by World Health Organization (WHO) criteria (2016) and have confirmed complete remission (CR) or complete remission with incomplete blood count recovery (CRi) following completion of intensive induction and consolidation chemotherapies.
    • Achieved first CR + CRi within 120 days of first dose of study drug or be no more than 75 days since last dose of intensive conventional (including both induction and consolidation) chemotherapies.
    • AML has intermediate or poor risk cytogenetics per National Comprehensive Cancer Network (NCCN) 2016 criteria.
  • (ECOG) performance status \<= 2.
  • Participant must have adequate hematologic, renal, and liver function laboratory values as described in the protocol.

Exclusion criteria

Exclusion Criteria:

  • History of acute promyelocytic leukemia (APL).
  • History of active central nervous system involvement with acute myeloid leukemia (AML).
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
112 participants (actual)

Study arms

  • Experimental
    Part 1: Dose Confirmation

    Participants will receive venetoclax once daily (QD) (Days 1-28) for up to 24 cycles, azacitidine (AZA) QD on Days 1-5 of each 28 day cycle for up to 6 cycles.

    Drug: Venetoclax · Drug: Azacitidine

  • Experimental
    Part 3 (Dose Finding): Dose Escalation

    Participants will receive venetoclax QD for up to 24 cycles, AZA QD on Days 1 to 14 of each 28-day cycle for up to 24 cycles to determine recommended phase 3 dose (RPTD).

    Drug: Venetoclax · Drug: Azacitidine

  • Experimental
    Part 3 (Dose Finding): Safety Expansion

    Participants will receive venetoclax QD for up to 24 cycles, AZA QD on Days 1 to 14 of each 28-day cycle for up to 24 cycles at the RPTD.

    Drug: Venetoclax · Drug: Azacitidine

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants With Dose-Limiting Toxicities (DLTs) of Venetoclax in Combination With Azacitidine (AZA) (Part 1)

    DLTs are any of the hematologic, nonhematologic toxicities, adverse events (AEs) occurring following administration of venetoclax as described in the protocol and evaluated by the Investigator and the sponsor.

    Time frame: Up to 28 days (Cycle 1)

  2. Number of Participants With DLTs of Venetoclax in Combination With Oral AZA (Part 3 Dose Finding Portion)

    DLTs are hematologic toxicities consisting of any Grade ≥ 3 neutropenia or thrombocytopenia lasting more than 7 days and nonhematologic toxicities as described in the protocol and evaluated by the Investigator and the Sponsor. In addition, AEs that lead to omitting \> 20% of the scheduled dose within the cycle is considered as a DLT unless clearly related to underlying disease. Treatment delay due to toxicity lasting greater than 14 days since the last dose of Venetoclax is also considered a DLT.

    Time frame: Up to 28 days (Cycle 1)

07

Results

Posted Aug 20, 2025

Participant flow

Participant flow — Overall Study
MilestonePart 1: Venetoclax 400 mg + Azacitidine 20 mg/m^2Part 1: Venetoclax 400 mg + Azacitidine 36 mg/m^2Part 1: Venetoclax 400 mg + Azacitidine 50 mg/m^2Part 3: Dose Level 1 - Venetoclax 400mg + CC-486 200mgPart 3: Dose Level 2 - Venetoclax 400mg + CC-486 300mg
Started2323203016
Completed00000
Not completed2323203016
Withdrew: Adverse event10010
Withdrew: Withdrawal by subject01111
Withdrew: Death14110
Withdrew: Physician decision12201
Withdrew: Covid-19 infection10000
Withdrew: Not disclosed53801
Withdrew: Missing10111
Withdrew: Continuing in ongoing study131372612

Outcome measures

PrimaryNumber of Participants With Dose-Limiting Toxicities (DLTs) of Venetoclax in Combination With Azacitidine (AZA) (Part 1)

DLTs are any of the hematologic, nonhematologic toxicities, adverse events (AEs) occurring following administration of venetoclax as described in the protocol and evaluated by the Investigator and the sponsor.

Time frame:
Up to 28 days (Cycle 1)
Reported as:
Count of participants · Participants
Number of Participants With Dose-Limiting Toxicities (DLTs) of Venetoclax in Combination With Azacitidine (AZA) (Part 1)
ParticipantsPart 1: Venetoclax 400 mg + Azacitidine 20 mg/m^2Part 1: Venetoclax 400 mg + Azacitidine 36 mg/m^2Part 1: Venetoclax 400 mg + Azacitidine 50 mg/m^2
Neutropenia344
Leukopenia100
Thrombocytopenia100
Platelet count decreased100
PrimaryNumber of Participants With DLTs of Venetoclax in Combination With Oral AZA (Part 3 Dose Finding Portion)

DLTs are hematologic toxicities consisting of any Grade ≥ 3 neutropenia or thrombocytopenia lasting more than 7 days and nonhematologic toxicities as described in the protocol and evaluated by the Investigator and the Sponsor. In addition, AEs that lead to omitting \> 20% of the scheduled dose within the cycle is considered as a DLT unless clearly related to underlying disease. Treatment delay due to toxicity lasting greater than 14 days since the last dose of Venetoclax is also considered a DLT.

Time frame:
Up to 28 days (Cycle 1)
Reported as:
Count of participants · Participants
Number of Participants With DLTs of Venetoclax in Combination With Oral AZA (Part 3 Dose Finding Portion)
ParticipantsPart 3: Dose Level 1 - Venetoclax 400mg + CC-486 200mgPart 3: Dose Level 2 - Venetoclax 400mg + CC-486 300mg
Neutropenia12
Thrombocytopenia11
Febrile neutropenia01
Fatigue01
Neutrophil count decreased11
Platelet count decreased01
Dizziness10

Adverse events

Collected over All-cause mortality and adverse event tables include events reported from the time of informed consent to the interim cutoff date of 05OCT2022. The median time on follow-up was 446, 687, 389 days for Part 1 VEN400_AZA20, VEN400_AZA36, VEN400_AZA50 and 67.5, 275 days for Part 3 Dose Level 1 (VEN400_CC200), Dose Level 2 (VEN400_CC300), respectively.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: Venetoclax 400 mg + Azacitidine 20 mg/m^23/23 (13%)5/23 (21.7%)21/23 (91.3%)
Part 1: Venetoclax 400 mg + Azacitidine 36 mg/m^25/23 (21.7%)7/23 (30.4%)22/23 (95.7%)
Part 1: Venetoclax 400 mg + Azacitidine 50 mg/m^21/20 (5%)5/20 (25%)20/20 (100%)
Part 3: Dose Level 1 - Venetoclax 400mg + CC-486 200mg1/30 (3.3%)5/30 (16.7%)29/30 (96.7%)
Part 3: Dose Level 2 - Venetoclax 400mg + CC-486 300mg1/16 (6.3%)3/16 (18.8%)16/16 (100%)
Most frequent serious events
Showing 10 of 23
Most frequent serious events
EventPart 1: Venetoclax 400 mg + Azacitidine 20 mg/m^2Part 1: Venetoclax 400 mg + Azacitidine 36 mg/m^2Part 1: Venetoclax 400 mg + Azacitidine 50 mg/m^2Part 3: Dose Level 1 - Venetoclax 400mg + CC-486 200mgPart 3: Dose Level 2 - Venetoclax 400mg + CC-486 300mg
FEBRILE NEUTROPENIABlood and lymphatic system disorders1/231/230/200/302/16
THROMBOCYTOPENIABlood and lymphatic system disorders2/231/231/201/300/16
NEUTROPENIABlood and lymphatic system disorders0/230/231/202/300/16
COLITISGastrointestinal disorders0/230/230/200/301/16
ANORECTAL INFECTIONInfections and infestations0/230/230/200/301/16
NEUTROPHIL COUNT DECREASEDInvestigations0/230/230/200/301/16
LEUKOPENIABlood and lymphatic system disorders0/230/231/200/300/16
COVID-19Infections and infestations0/230/231/200/300/16
COVID-19 PNEUMONIAInfections and infestations1/231/231/200/300/16
ACUTE KIDNEY INJURYRenal and urinary disorders0/230/231/200/300/16
Most frequent other events
Showing 10 of 121
Most frequent other events
EventPart 1: Venetoclax 400 mg + Azacitidine 20 mg/m^2Part 1: Venetoclax 400 mg + Azacitidine 36 mg/m^2Part 1: Venetoclax 400 mg + Azacitidine 50 mg/m^2Part 3: Dose Level 1 - Venetoclax 400mg + CC-486 200mgPart 3: Dose Level 2 - Venetoclax 400mg + CC-486 300mg
NEUTROPENIABlood and lymphatic system disorders13/2316/2316/2010/309/16
THROMBOCYTOPENIABlood and lymphatic system disorders8/2313/2311/207/306/16
NAUSEAGastrointestinal disorders6/233/234/2015/309/16
VOMITINGGastrointestinal disorders3/232/230/209/309/16
DIARRHOEAGastrointestinal disorders6/232/235/2013/307/16
COVID-19Infections and infestations2/235/232/203/306/16
ANAEMIABlood and lymphatic system disorders4/238/237/203/304/16
LEUKOPENIABlood and lymphatic system disorders6/237/237/204/304/16
PLATELET COUNT DECREASEDInvestigations4/233/233/203/305/16
CONSTIPATIONGastrointestinal disorders1/235/231/208/303/16

Baseline characteristics

Age, Continuous
Age, Continuous(years)Part 1: Venetoclax 400 mg + Azacitidine 20 mg/m^2Part 1: Venetoclax 400 mg + Azacitidine 36 mg/m^2Part 1: Venetoclax 400 mg + Azacitidine 50 mg/m^2Part 3: Dose Level 1 - Venetoclax 400mg + CC-486 200mgPart 3: Dose Level 2 - Venetoclax 400mg + CC-486 300mgTotal
Mean53.1 ± 13.9757.3 ± 13.8955.6 ± 16.2658.8 ± 12.7054.1 ± 16.9455.78 ± 14.75
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: Venetoclax 400 mg + Azacitidine 20 mg/m^2Part 1: Venetoclax 400 mg + Azacitidine 36 mg/m^2Part 1: Venetoclax 400 mg + Azacitidine 50 mg/m^2Part 3: Dose Level 1 - Venetoclax 400mg + CC-486 200mgPart 3: Dose Level 2 - Venetoclax 400mg + CC-486 300mgTotal
Female13111016656
Male101210141056
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Part 1: Venetoclax 400 mg + Azacitidine 20 mg/m^2Part 1: Venetoclax 400 mg + Azacitidine 36 mg/m^2Part 1: Venetoclax 400 mg + Azacitidine 50 mg/m^2Part 3: Dose Level 1 - Venetoclax 400mg + CC-486 200mgPart 3: Dose Level 2 - Venetoclax 400mg + CC-486 300mgTotal
American Indian or Alaska Native000000
Asian6685227
Native Hawaiian or Other Pacific Islander000000
Black or African American000000
White171612251484
More than one race010001
Unknown or Not Reported000000
08

Study locations

156 sites
  • Mitchell Cancer Institute /ID# 216443
    Mobile, Alabama 36604, United States
  • Compassionate Cancer Care Research Group - Fountain Valley /ID# 216156
    Fountain Valley, California 92708-7501, United States
  • University of California, Los Angeles /ID# 219149
    Los Angeles, California 90095, United States
  • Colorado Blood Cancer Institute /ID# 214280
    Denver, Colorado 80218, United States
  • St. Alphonsus Regional Medical /ID# 216424
    Boise, Idaho 83706, United States
  • Duplicate_Rush University Medical Center /ID# 218815
    Chicago, Illinois 60612, United States
  • University of Kentucky Markey Cancer Center /ID# 215048
    Lexington, Kentucky 40536-7001, United States
  • Duplicate_Norton Cancer Institute /ID# 216401
    Louisville, Kentucky 40202-3700, United States
  • Tulane Medical Center - New Orleans /ID# 218166
    New Orleans, Louisiana 70112-2600, United States
  • Duplicate_Ochsner Clinic Foundation-New Orleans /ID# 214583
    New Orleans, Louisiana 70121, United States
  • Tufts Medical Center /ID# 216110
    Boston, Massachusetts 02111-1552, United States
  • Massachusetts General Hospital /ID# 217307
    Boston, Massachusetts 02114, United States
  • Duplicate_UMass Chan Medical School /ID# 218163
    Worcester, Massachusetts 01655, United States
  • Oncology Hematology Associates (OHA) - Springfield /ID# 216351
    Springfield, Missouri 65807-5287, United States
  • Saint Louis University Cancer Center /ID# 218164
    St Louis, Missouri 63110-2539, United States
  • The John Theurer Cancer /ID# 215191
    Hackensack, New Jersey 07601, United States
  • Rutgers Cancer Institute of New Jersey /ID# 239708
    New Brunswick, New Jersey 08901, United States
  • Weill Cornell Medical College /ID# 214847
    New York, New York 10065, United States
  • Providence Portland Medical Ct /ID# 216231
    Portland, Oregon 97213-2933, United States
  • Fox Chase Cancer Center /ID# 239372
    Philadelphia, Pennsylvania 19111, United States
  • UPMC Hillman Cancer Ctr /ID# 214051
    Pittsburgh, Pennsylvania 15232, United States
  • Duplicate_Prisma Health Cancer Institute-Faris Road /ID# 216066
    Greenville, South Carolina 29605-4255, United States
  • St Francis Cancer Center /ID# 216115
    Greenville, South Carolina 29607-5253, United States
  • Gibbs Cancer Center & Research /ID# 216192
    Spartanburg, South Carolina 29303-3040, United States
  • Tennessee Oncology-Nashville Centennial /ID# 218757
    Nashville, Tennessee 37203-1632, United States
  • Texas Oncology- Baylor Charles A. Sammons Cancer Center /ID# 214584
    Dallas, Texas 75246-2003, United States
  • University of Texas MD Anderson Cancer Center /ID# 225201
    Houston, Texas 77030, United States
  • St George Hospital /ID# 215416
    Kogarah, New South Wales 2217, Australia
  • Liverpool Hospital /ID# 215415
    Liverpool, New South Wales 2170, Australia
  • Shoalhaven District Memorial Hospital /ID# 221973
    Nowra, New South Wales 2541, Australia
  • Wollongong Hospital /ID# 216071
    Wollongong, New South Wales 2500, Australia
  • Gold coast University Hospital /ID# 214650
    Southport, Queensland 4215, Australia
  • Toowoomba Hospital /ID# 217922
    Toowoomba, Queensland 4350, Australia
  • Princess Alexandra Hospital /ID# 238753
    Woolloongabba, Queensland 4102, Australia
  • Royal Adelaide Hospital /ID# 238754
    Adelaide, South Australia 5000, Australia
  • Box Hill Hospital /ID# 217622
    Box Hill, Victoria 3128, Australia
  • Barwon Health /ID# 217921
    Geelong, Victoria 3220, Australia
  • Perth Blood Institute Ltd /ID# 217531
    Nedlands, Western Australia 6009, Australia
  • Tom Baker Cancer Centre /ID# 214625
    Calgary, Alberta T2N 4N2, Canada
  • Duplicate_University of Alberta Hospital - Division of Hematology /ID# 215656
    Edmonton, Alberta T6G 2B7, Canada
  • Juravinski Cancer Centre /ID# 214623
    Hamilton, Ontario L8V 1C3, Canada
  • London Health Sciences Center- University Hospital /ID# 216055
    London, Ontario N6A 5W9, Canada
  • Ottawa Hospital Research Institute /ID# 214627
    Ottawa, Ontario K1H 8L6, Canada
  • University Health Network_Princess Margaret Cancer Centre /ID# 214624
    Toronto, Ontario M5G 2M9, Canada
  • Duplicate_McGill University Health Center Research Institute /ID# 215984
    Montreal, Quebec H4A 3J1, Canada
  • Beijing Friendship Hospital /ID# 216455
    Beijing, Beijing Municipality 100032, China
  • Chinese PLA General Hospital /ID# 216286
    Beijing, Beijing Municipality 100853, China
  • Peking University International Hospital /ID# 217439
    Beijing, Beijing Municipality 102206, China
  • Guangdong Provincial People's Hospital /ID# 216284
    Guangzhou, Guangdong 510080, China
  • Nanfang Hospital of Southern Medical University /ID# 215565
    Guangzhou, Guangdong 510515, China
  • Henan Cancer Hospital /ID# 215566
    Zhengzhou, Henan 450008, China
  • Union Hospital Tongji Medical College Huazhong University of Science and Technol /ID# 218046
    Wuhan, Hubei 430022, China
  • Tongji Hospital Tongji Medical College of HUST /ID# 216456
    Wuhan, Hubei 430030, China
  • Duplicate_Shanghai Tongji Hospital /ID# 218800
    Shanghai, Shanghai Municipality 200065, China
  • Tangdu Hospital of The Fourth Military Medical University, PLA /ID# 216283
    Xi’an, Shanxi 710038, China
  • West China Hospital, Sichuan University /ID# 216606
    Chengdu, Sichuan 610041, China
  • Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc /ID# 215558
    Tianjin, Tianjin Municipality 300020, China
  • The First Affiliated Hospital, Zhejiang University School of Medicine /ID# 215564
    Hangzhou, Zhejiang 310003, China
  • Fakultní Nemocnice Brno - Jihlavská /ID# 214807
    Brno, Brno-mesto 625 00, Czechia
  • Fakultni Nemocnice Ostrava /ID# 214809
    Ostrava, Ostrava-mesto 708 52, Czechia
  • Ustav hematologie a krevni transfuze /ID# 215137
    Prague, 128 00, Czechia
  • Chu de Nice-Hopital L'Archet Ii /Id# 217368
    Nice, Alpes-Maritimes 06202, France
  • Duplicate_CHU Bordeaux - Hopital Haut Leveque /ID# 215150
    Pessac, Gironde 33604, France
  • CHRU Tours - Hopital Bretonneau /ID# 216186
    Tours, Indre-et-Loire 37044, France
  • CHRU Lille - Hopital Claude Huriez /ID# 217474
    Lille, Nord 59037, France
  • Duplicate_CHU de Nantes - Hotel Dieu /ID# 217367
    Nantes, Pays de la Loire Region 44000, France
  • Centre Hospitalier de la Cote Basque /ID# 216185
    Bayonne, Pyrenees-Atlantiques 64100, France
  • Centre Hospitalier du Mans /ID# 215148
    Le Mans, Sarthe 72037, France
  • Institut Gustave Roussy /ID# 215158
    Villejuif, Val-de-Marne 94805, France
  • Chu Angers /Id# 215151
    Angers, 49933, France
  • Duplicate_Hopital Henri Mondor /ID# 215159
    Créteil, 94000, France
  • Centre Hospitalier de Versailles André Mignot /ID# 215157
    Le Chesnay, 78150, France
  • Hopital Avicenne - APHP /ID# 215152
    Bobigny, Île-de-France Region 93000, France
  • Universitaetsklinikum Giessen und Marburg /ID# 214734
    Marburg, Hesse 35043, Germany
  • Duplicate_Klinikum Chemnitz gGmbH /ID# 216073
    Chemnitz, Saxony 09116, Germany
  • Universitaetsklinikum Leipzig /ID# 214440
    Leipzig, Saxony 04103, Germany
  • Universitaetsklinikum Schleswig-Holstein Campus Luebeck /ID# 215173
    Lübeck, Schleswig-Holstein 23538, Germany
  • Universitaetsklinikum Halle (Saale) /ID# 221109
    Halle, 06120, Germany
  • General Hospital of Athens Laiko /ID# 213869
    Athens, Attica 11527, Greece
  • University General Hospital Attikon /ID# 214298
    Athens, Attica 12462, Greece
  • University General Hospital of Heraklion PA.G.N.I /ID# 214075
    Heraklion, Crete 71500, Greece
  • General University Hospital of Alexandroupolis /ID# 213870
    Alexandroupoli, 68100, Greece
  • General Hospital of Athens Evaggelismos and Ophthalmiatrio of Athens Polyclinic /ID# 213872
    Athens, 10676, Greece
  • University General Hospital of Patras /ID# 213871
    RION Patras Achaia, 26504, Greece
  • Debreceni Egyetem-Klinikai Kozpont /ID# 214422
    Debrecen, Hajdú-Bihar 4032, Hungary
  • Somogy Varmegyei Kaposi Mor Oktato Korhaz /ID# 214426
    Kaposvár, Somogy County 7400, Hungary
  • Szabolcs-Szatmar-Bereg Varmegyei Oktatokorhaz /ID# 214425
    Nyíregyháza, Szabolcs-Szatmár-Bereg 4400, Hungary
  • Vas Varmegyei Markusovszky Egyetemi Oktatokorhaz /ID# 215644
    Szombathely, Vas County 9700, Hungary
  • Duplicate_Semmelweis Egyetem /ID# 214423
    Budapest, 1085, Hungary
  • Shaare Zedek Medical Center /ID# 239699
    Jerusalem, Jerusalem 91031, Israel
  • Hadassah Medical Center-Hebrew University /ID# 239700
    Jerusalem, Jerusalem 91120, Israel
  • Tel Aviv Sourasky Medical Center /ID# 239698
    Tel Aviv, Tel Aviv 6423906, Israel
  • Rabin Medical Center /ID# 239696
    Petah Tikva, 4941492, Israel
  • Duplicate_IRCCS AOU di Bologna - Policlinico Sant'Orsola-Malpighi /ID# 213948
    Bologna, Emilia-Romagna 40138, Italy
  • Duplicate_Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico /ID# 214826
    Milan, Milano 20122, Italy
  • ASST Grande Ospedale Metropolitano Niguarda /ID# 213946
    Milan, Milano 20162, Italy
  • A.O.U. CITTA' DELLA SALUTE E DELLA SCIENZA DI TORINO - Ospedale Molinette /ID# 214505
    Turin, Piedmont 10126, Italy
  • Duplicate_Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona /ID# 213944
    Ancona, 60126, Italy
  • ASST degli Spedali Civili di Brescia /ID# 214580
    Brescia, 25123, Italy
  • Duplicate_A.O.U. Policlinico G. Rodolico S.Marco- Presidio G.Rodolico /ID# 214802
    Catania, 95123, Italy

Showing the first 100 of 156 sites across 19 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Ivanov V, Yeh SP, Mayer J, Saini L, Unal A, Boyiadzis M, Hoffman DM, Kang K, Addo SN, Mendes WL, Fathi AT. Design of the VIALE-M phase III trial of venetoclax and oral azacitidine maintenance therapy in acute myeloid leukemia. Future Oncol. 2022 Aug;18(26):2879-2889. doi: 10.2217/fon-2022-0450. Epub 2022 Jul 19. PubMed 35852098 ↗
  • Shallis RM, Podoltsev NA. Maintenance therapy for acute myeloid leukemia: sustaining the pursuit for sustained remission. Curr Opin Hematol. 2021 Mar 1;28(2):110-121. doi: 10.1097/MOH.0000000000000637. PubMed 33394722 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: For details on when studies are available for sharing visit https://vivli.org/ourmember/abbvie/

Access criteria: To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/

Data sharing details ↗ · vivli.org

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2020 to primary completion in Sep 2022, 30 months.

Results were first posted in Aug 2025, 2 years 10 months after primary completion. A results delay was requested in Aug 2023.

Of 43 industry-sponsored phase 3 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 62. This study's 30 months is below that.

Counting every sponsor, half of 121 studies reached it within 74 months; a quarter within 39 and three quarters within 99.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2019
First posted
Sep 25, 2019
StartActual
Mar 26, 2020
Primary completionActual
Sep 29, 2022
CompletionActual
Feb 20, 2026
Results delay requested
Aug 29, 2023
Results first posted
Aug 20, 2025
Last update
Apr 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04102020
Lead sponsor
AbbVie
Collaborators
Roche-Genentech
Responsible party
Sponsor
First posted
Sep 25, 2019
Start date
Mar 26, 2020
Primary completion
Sep 29, 2022
Completion
Feb 20, 2026
Results posted
Aug 20, 2025
Last update
Apr 8, 2026

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Venetoclax · Azacitidine

Start the discussion